INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 212 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $413,164 | -71.8% | 22,285 | -37.0% | 0.00% | -63.6% |
| Q3 2020 | $1,466,000 | -9.8% | 35,357 | +4.1% | 0.01% | -15.4% |
| Q2 2020 | $1,626,000 | +12.6% | 33,949 | +48.0% | 0.01% | -13.3% |
| Q1 2020 | $1,444,000 | -58.4% | 22,933 | -18.0% | 0.02% | -42.3% |
| Q4 2019 | $3,467,000 | +69.9% | 27,977 | -9.1% | 0.03% | +62.5% |
| Q3 2019 | $2,041,000 | -17.1% | 30,762 | -0.5% | 0.02% | -20.0% |
| Q2 2019 | $2,461,000 | -22.9% | 30,929 | +8.3% | 0.02% | -23.1% |
| Q1 2019 | $3,194,000 | +14.2% | 28,550 | +2.8% | 0.03% | +8.3% |
| Q4 2018 | $2,798,000 | -26.5% | 27,763 | -7.9% | 0.02% | -4.0% |
| Q3 2018 | $3,809,000 | +25.0% | 30,146 | -17.0% | 0.02% | +25.0% |
| Q2 2018 | $3,048,000 | +294.8% | 36,327 | +189.2% | 0.02% | +900.0% |
| Q1 2018 | $772,000 | -64.2% | 12,561 | -66.0% | 0.00% | -60.0% |
| Q4 2017 | $2,157,000 | -19.5% | 36,911 | -20.1% | 0.01% | -16.7% |
| Q3 2017 | $2,681,000 | -24.2% | 46,191 | +58.0% | 0.01% | -33.3% |
| Q2 2017 | $3,539,000 | +12.2% | 29,231 | +4.8% | 0.01% | 0.0% |
| Q1 2017 | $3,155,000 | +4.1% | 27,891 | -0.0% | 0.01% | 0.0% |
| Q4 2016 | $3,031,000 | -34.1% | 27,901 | -0.1% | 0.01% | -35.7% |
| Q3 2016 | $4,596,000 | +10.6% | 27,926 | -4.2% | 0.01% | +7.7% |
| Q2 2016 | $4,157,000 | +2.0% | 29,136 | -8.1% | 0.01% | 0.0% |
| Q1 2016 | $4,075,000 | -33.2% | 31,716 | -22.3% | 0.01% | -27.8% |
| Q4 2015 | $6,097,000 | -36.2% | 40,824 | -29.2% | 0.02% | -37.9% |
| Q3 2015 | $9,563,000 | -25.3% | 57,656 | +8.7% | 0.03% | -9.4% |
| Q2 2015 | $12,800,000 | +10.2% | 53,027 | +28.8% | 0.03% | +18.5% |
| Q1 2015 | $11,615,000 | +46.6% | 41,186 | -18.9% | 0.03% | +35.0% |
| Q4 2014 | $7,922,000 | +13.4% | 50,782 | +72.1% | 0.02% | +17.6% |
| Q3 2014 | $6,985,000 | +9.9% | 29,510 | +9.9% | 0.02% | +6.2% |
| Q2 2014 | $6,357,000 | -24.1% | 26,863 | +5.7% | 0.02% | -33.3% |
| Q1 2014 | $8,381,000 | +120.3% | 25,412 | -54.4% | 0.02% | +100.0% |
| Q4 2013 | $3,804,000 | – | 55,714 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |